Bazedoxifene, originally approved by the FDA for managing postmenopausal osteoporosis as part of the combination therapy Duavee with conjugated estrogens [43], has also been identified as a novel inhibitor by blocking IL-6 and GP130 interaction [44]. This evidence concerns the gene IL6 and postmenopausal osteoporosis.